Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: final results of the phase 2 …
E Terpos, I Ntanasis‐Stathopoulos… - American Journal of …, 2024 - Wiley Online Library
The use of lenalidomide in frontline therapy for patients with newly diagnosed multiple
myeloma (MM) has increased the number of those who become refractory to lenalidomide at …
myeloma (MM) has increased the number of those who become refractory to lenalidomide at …
Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in …
X Han, X Jiang, J He, G Zheng, Y Xiong… - Cancer …, 2024 - Wiley Online Library
Background Comparative investigations evaluating the efficacy of pomalidomide‐based
(Pom‐based) versus daratumumab‐based (Dara‐based) therapies in patients with …
(Pom‐based) versus daratumumab‐based (Dara‐based) therapies in patients with …
Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations
The combination of anti‐CD38 monoclonal antibodies to a proteasome inhibitor, an
immunomodulatory agent and dexamethasone (quadruplet—QUAD) in sequence with …
immunomodulatory agent and dexamethasone (quadruplet—QUAD) in sequence with …
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed …
Abstract Objectives and Methods We conducted a multicenter retrospective study to analyze
the safety and efficacy of DPd versus DKd in daratumumab naïve RRMM patients treated in …
the safety and efficacy of DPd versus DKd in daratumumab naïve RRMM patients treated in …
Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma
R Popat, SJ Chavda - The Lancet Haematology, 2023 - thelancet.com
Comment www. thelancet. com/haematology Vol 10 October 2023 e789 12· 4 months [95%
CI 8· 3–19· 3] vs 6· 9 months [5· 5–9· 3]; HR 0· 63 [95% CI 0· 47–0· 85]; p= 0· 0018). 10 In this …
CI 8· 3–19· 3] vs 6· 9 months [5· 5–9· 3]; HR 0· 63 [95% CI 0· 47–0· 85]; p= 0· 0018). 10 In this …
Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data
BA Derman, J Ambrose, LL Fernandes… - Blood …, 2024 - ashpublications.org
Daratumumab (dara)-based triplet therapies are commonly used in the second-line (2L) and
third-line (3L) settings in relapsed/refractory multiple myeloma (RRMM), usually in …
third-line (3L) settings in relapsed/refractory multiple myeloma (RRMM), usually in …